Chemotherapy Market Information: By Drugs (Alkylating Agents, Antimetabolites), by Route of Drug Administration (Oral, Intravenous), by Indication (Leukemia, Lymphoma, Breast Cancer), End-User (Hospitals, Research Institute) - Global Forecast Till 2023
Chemotherapy is a type of cancer treatment which involves the use of one or more chemotherapeutic agents such as anti-cancer drugs. The treatment prevents the cancer cells division and growth of cancer cells by killing the dividing cells. It is used for the treatment of various types of cancer such as lung cancer, breast cancer, leukemia, myeloma, sarcoma, lymphoma, ovarian cancer, and others. The chemotherapy drugs can be administered directly into the bloodstream or can be targeted to specific cancer sites. However, the treatment has various side effects such as nausea and vomiting, alopecia, hair loss, fatigue, hearing impairment, mucositis, loss of appetite, and many others.
The global chemotherapy market is driven by the increasing prevalence of various types of cancers such as lung cancer, sarcoma, lymphoma, breast cancer, myeloma, and others. Additionally, the technological advancement and increasing emphasis on research and development in the field of oncology fuel the growth of the market. However, the high cost of treatment and poor reimbursement policies in the developing regions are some of the factors which may restrain the market growth during the forecast period. As per the data from Cancer Research U.K. in 2012, 14.1 million of new cancer cases were registered globally, and the prevalence of different types of cancer is increasing continuously.
Global chemotherapy cancer market is expected to grow at a CAGR of 6.2% during the forecast period, 2017–2023.
Figure: Global Chemotherapy Market, by Region, 2016 (%)
Sources: Annual reports, Press release, White paper, Company presentation
- Medical Oncologists
- Oncology Nurses
- Medical Companies
- Research and Development (R&D) Companies
- Government Research Institutes
- Academic Institutes and Universities
The global chemotherapy market is segmented on the basis of drugs, indication, route of drug administration, and end-user.
On the basis of drugs, it is segmented into alkylating agents, antimetabolites, anti-tumor antibiotics, topoisomerase inhibitors, mitotic inhibitors, and others. Alkylating agents are further segmented into mustard gas derivatives, ethylenimines, alkyl sulfonates, hydrazines and triazines, and others. Anti-tumor antibiotics are further segmented into anthracyclines and chromomycin. Topoisomerase inhibitors are further segmented into Topoisomerase I inhibitors and Topoisomerase II inhibitors.
On the basis of indication, the market is segmented into leukemia, lymphoma, breast cancer, ovarian cancer, lung cancer, myeloma, sarcoma, and others.
On the basis of route of drug administration, the market is segmented into oral and intravenous.
On the basis of end-user, it is segmented into hospitals, research institutes, and others.
Sources: Annual reports, Press release, White paper, and Company presentation
The American chemotherapy market is driven by the increasing number of market players manufacturing chemotherapy drugs, the increasing patient population, and the increase in healthcare expenditure. Additionally, the changing lifestyle and addiction to smoking and alcohol also fuel the market growth. Moreover, available healthcare facilities and use of modern technologies in cancer research and treatment also influence the market growth. The National Cancer Institute estimated that 14 million people had cancer in 2014, in America and the number is expected to increase and reach to 19 million by 2024.
In Europe, the market is driven by the increasing government support for research and development and the increasing number of pharmaceutical companies engaged in research for the treatment of various types of cancer. Germany and France are the largest contributors to the market growth due to increasing investments in healthcare and cancer research.
Asia Pacific is the fastest growing market for chemotherapy due to an increasing demand for chemotherapy drugs and the availability of well-qualified and skilled healthcare professionals such as oncologists and also due to the rapid growth of the healthcare sector.
In the Middle East and Africa, the increasing awareness about various types of cancer, their diagnosis, and available treatment options drive the market growth.
Some of the key players in the market are Sanofi (France), Novartis (Germany), Pfizer Inc. (U.S.), Eli Lilly & Company (U.S.), ImClone Systems Inc. (U.S.), GlaxoSmithKline (U.K.), AstraZeneca (U.K), Schering-Plough (U.S.), Boehringer Ingelheim (Germany), Bristol-Myers Squibb , Teva Pharmaceuticals Industries (Japan), F. Hoffmann-La Roche Ltd ( Switzerland), Merck & Co., Inc. (U.S.), Chemo Espana SL (Spain), CELGENE CORPORATION (U.S.), Amgen Inc (U.S.), Bayer AG (Germany), Takeda Pharmaceutical Company Limited (Japan), and others.